Maria Resilde Natale

Dr. Maria Resilde Natale

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
TFTeresa Vanessa Fiorentino
Teresa Vanessa Fiorentino
FVFrancesca De Vito
Francesca De Vito
MNMaria Resilde Natale
Maria Resilde Natale
SSSilvia Sergi
Silvia Sergi
MRMariangela Rubino
Mariangela Rubino
GSGiorgio Sesti
Giorgio Sesti
Recently, the International Diabetes Federation (IDF) has recommended determination of 1 h-post-load glucose (PG) to diagnose intermediate hyperglycemia (IH) and type 2 diabetes (T2DM). Herein, we investigate the implication of IDF recommendation in identifying subjects with chronic kidney disease (CKD). Estimated glomerular filtration rate (eGFR) was assessed on 2161 subjects classified on the basis of their fasting, 1 h and 2 h-PG, according to the IDF criteria, as having normal glucose tolerance (NGT), isolated impaired fasting glucose (iIFG), IH and T2DM. Prevalence of CKD (eGFR < 60 ml/min/1.73 m2) and mildly reduced kidney function (eGFR 90-60 ml/min/1.73 m2) progressively increased at worsening of glucose tolerance. In a logistic regression analysis adjusted for several cardio-metabolic confounders, individuals with iIFG and IH exhibited a 3.48- (95 %CI = 1.01-11.00, P = 0.05) and 3.69- (95 %CI = 1.42-9.60, P = 0.007) fold increased risk of having CKD compared to the NGT group. The risk for CKD was further increased in subjects with T2DM (OR = 3.93, 95 %CI = 1.36-10.66, P = 0.007). Additionally, participants with IH and T2DM had a 1.89-fold (95 %CI = 1.38-2.60, P < 0.0001) and 2.78-fold (95 %CI = 1.97-3.98, P < 0.0001) higher risk of mildly reduced GFR compared to the NGT group. The 1 h-PG thresholds proposed by IDF as diagnostic for IH and T2DM are capable of identifying individuals at risk of kidney dysfunction.

23 May 2025 in Life
Verified
Journal Article
Open access
PDF file
VTVincenzo Trapanese
Vincenzo Trapanese
ADAnnamaria Dagostino
Annamaria Dagostino
MNMaria Resilde Natale
Maria Resilde Natale
FGFederica Giofrè
Federica Giofrè
CVClara Vatalaro
Clara Vatalaro
FAFranco Arturi
Franco Arturi
Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis. The recent emergence of novel antidiabetic medications has been demonstrated to exert a favourable influence on the composition of the intestinal microbiota. Incretin-based therapy exerts a multifaceted influence on the composition of the gut microbiota, leading to alterations in bacterial flora. Of particular significance is the capacity of numerous metabolites produced by the gut microbiota to modulate the activity and hormonal secretion of enteroendocrine cells. This review examines the effects of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/gastric inhibitory polypeptide (GIP) receptor dual agonists on the composition of the gut microbiota in both mice and human subjects. The nature of this interaction is complex and bidirectional. The present study demonstrates the involvement of the incretinic axis in modulating the microbial composition, with the objective of providing novel preventative strategies and potential personalised therapeutic targets for obesity and T2DM.

26 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MMMattia Massimino
Mattia Massimino
MRMariangela Rubino
Mariangela Rubino
MNMaria Resilde Natale
Maria Resilde Natale
LSLuca Salerno
Luca Salerno
SBStefania Belviso
Stefania Belviso
Francesco AndreozziFrancesco Andreozzi
Francesco Andreozzi
Background: Type 2 diabetes mellitus represents a global health challenge, with chronic hyperglycemia leading to a spectrum of microvascular and macrovascular complications. This narrative review provides a comprehensive and integrated analysis of the nerve growth factor (NGF) axis as a key, yet underrecognized, pathogenic mechanism. Methods: This narrative review was conducted in accordance with scholarly standards for non-systematic syntheses (SANRA). We included both clinical and preclinical studies focusing on NGF/proNGF biology and interventions across major diabetes complications. Discussion: Growing evidence highlights NGF as a pivotal mediator at the crossroads of neuronal, vascular and metabolic pathways. In diabetes, a disrupted balance between mature NGF and its precursor proNGF, favors the detrimental p75NTR pathway, leading to increased cellular stress, inflammation and apoptosis. In this narrative review, we examine how a decline in mature NGF and a relative excess of proNGF contribute to the pathophysiology of diabetic complications across various organ systems. We highlight the dual role of the NGF axis: while NGF-TrkA signaling consistently confers neuroprotective and vasculoprotective benefits, unchecked proNGF-p75NTR activity amplifies tissue damage. Conclusions: Collectively, the evidence identifies NGF as a candidate biomarker for both early tissue distress and therapeutic monitoring. We conclude by outlining key priorities for future research, including the development of standardized assays and the initiation of well-designed clinical trials to translate these promising strategies for early detection and treatment of diabetes-related complications.

3 July 2024 in Italian Journal of Medicine
Verified
Journal Article
Open access
PDF file
VTVincenzo Trapanese
Vincenzo Trapanese
MPMaria Chiara Pelle
Maria Chiara Pelle
MCMaria Capria
Maria Capria
NCNazareno Carullo
Nazareno Carullo
CVClara Vatalaro
Clara Vatalaro
FAFranco Arturi
Franco Arturi
The very low-calorie ketogenic diet (VLCKD), characterized by a marked energy restriction that induces rapid weight loss, has recently been proposed as a valid nutritional strategy for managing obesity. VLCKD is commonly considered dangerous for the kidneys due to the misconception that it is high in protein, beyond the risk of electrolyte imbalances and an increase in diuresis. We report a case of safe and effective weight loss induced by VLCKD in a 43-year-old Caucasian woman with a recent episode of acute kidney injury on advanced chronic kidney disease. Surprisingly, we observed that after the diet-induced weight loss, not only did renal function not worsen, but proteinuria also improved. The principal value of this case report is its singular demonstration of impressive weight loss induced by VLCKD in a complex obese patient that was apparently not accompanied by the development of serious adverse sequelae.